Edgestream Partners L.P. Buys Shares of 24,106 Intra-Cellular Therapies, Inc. (NASDAQ:ITCI)

Edgestream Partners L.P. purchased a new position in shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 24,106 shares of the biopharmaceutical company’s stock, valued at approximately $1,526,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Allworth Financial LP grew its holdings in shares of Intra-Cellular Therapies by 104.0% during the second quarter. Allworth Financial LP now owns 667 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 340 shares during the last quarter. Harbor Capital Advisors Inc. bought a new stake in shares of Intra-Cellular Therapies during the second quarter worth about $46,000. Coppell Advisory Solutions Corp. bought a new stake in shares of Intra-Cellular Therapies during the fourth quarter worth about $47,000. Global Retirement Partners LLC grew its holdings in shares of Intra-Cellular Therapies by 3,750.0% during the first quarter. Global Retirement Partners LLC now owns 1,540 shares of the biopharmaceutical company’s stock worth $97,000 after purchasing an additional 1,500 shares during the last quarter. Finally, US Bancorp DE grew its holdings in shares of Intra-Cellular Therapies by 25.9% during the first quarter. US Bancorp DE now owns 1,641 shares of the biopharmaceutical company’s stock worth $89,000 after purchasing an additional 338 shares during the last quarter. 86.94% of the stock is currently owned by institutional investors.

Intra-Cellular Therapies Stock Performance

Shares of ITCI opened at $58.56 on Tuesday. Intra-Cellular Therapies, Inc. has a 52-week low of $42.01 and a 52-week high of $67.05. The business’s 50 day moving average price is $53.19 and its two-hundred day moving average price is $58.29. The firm has a market cap of $5.64 billion, a PE ratio of -36.37 and a beta of 1.04.

Insider Buying and Selling at Intra-Cellular Therapies

In other Intra-Cellular Therapies news, CEO Sharon Mates sold 55,587 shares of the business’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $53.76, for a total value of $2,988,357.12. Following the transaction, the chief executive officer now directly owns 1,094,722 shares of the company’s stock, valued at $58,852,254.72. The sale was disclosed in a legal filing with the SEC, which is available through this link. In other news, CEO Sharon Mates sold 55,587 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $53.76, for a total transaction of $2,988,357.12. Following the transaction, the chief executive officer now directly owns 1,094,722 shares of the company’s stock, valued at $58,852,254.72. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Mark Neumann sold 42,393 shares of the company’s stock in a transaction that occurred on Monday, November 6th. The stock was sold at an average price of $55.63, for a total value of $2,358,322.59. Following the transaction, the executive vice president now directly owns 29,700 shares in the company, valued at $1,652,211. The disclosure for this sale can be found here. Insiders own 3.40% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently weighed in on ITCI. Needham & Company LLC boosted their price target on Intra-Cellular Therapies from $71.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Royal Bank of Canada reduced their target price on Intra-Cellular Therapies from $77.00 to $76.00 and set an “outperform” rating on the stock in a report on Friday, November 3rd. StockNews.com assumed coverage on Intra-Cellular Therapies in a report on Thursday, October 5th. They issued a “hold” rating on the stock. Morgan Stanley reiterated an “overweight” rating and issued a $80.00 target price on shares of Intra-Cellular Therapies in a report on Friday, August 4th. Finally, Cantor Fitzgerald upped their target price on Intra-Cellular Therapies from $98.00 to $101.00 and gave the company an “overweight” rating in a report on Friday, November 3rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.67.

Intra-Cellular Therapies Profile

Intra-Cellular Therapies, Inc, a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States.